A Statement from our Founder,
CEO and Director Scott Tarriff
April 16, 2020
Eagle has always been deeply committed to developing innovative medicines that meaningfully improve patients’ lives, and this mission remains as important as ever during the global pandemic. Although we are a relatively small company with a dedicated employee base of just over 100 professionals, Eagle is proud to join the effort to identify effective treatments for COVID-19 patients and address the impact of the SARS-CoV-2 virus.
Eagle has worked for many years to understand how RYANODEX® (dantrolene sodium) for injectable suspension impacts the complex process of calcium regulation in cells. This work has served as the basis for Eagle to study a number of different diseases and disorders in which intracellular calcium dysregulation may be an important factor.
We believe that an altered intracellular calcium balance may enhance virus replication. Because of this, intracellular calcium levels may be an important factor in some viral infections. Based on novel insights derived from its earlier work using RYANODEX®, Eagle recently conducted controlled in vitro laboratory tests, in which RYANODEX® inhibited the growth of SARS- CoV-2 (the virus causing the COVID-19 pandemic). Based on these promising results, Eagle intends to initiate a clinical trial this month in partnership with Hackensack University Medical Center to evaluate the efficacy and safety of RYANODEX® in COVID-19 patients.  To read more about the latest news on this effort, please click here.
Since the beginning of the COVID-19 outbreak, Eagle has been committed to the safety of our employees and to the patients and health care providers who rely on our products. Accordingly, we have taken precautions to help ensure the safety and well-being of our team members, and we have implemented processes and technologies to minimize disruption to our business. Eagle continues to actively monitor this rapidly evolving situation so that we can take additional steps as needed.
We salute the health care providers working on the front lines to help those affected by the COVID-19 and the many workers across our country providing essential services. We are all in this together, and we are grateful to be a part of the effort to address this public health crisis.
Chief Executive Officer of Eagle Pharmaceuticals
 RYANODEX® (dantrolene sodium) for injectable suspension is an investigational drug not yet approved by the United States Food and Drug Administration for the treatment of patients with COVID-19. RYANODEX® is currently approved for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk. For more information about RYANODEX®, please visit: www.ryanodex.com